Somatropin 191aa 10 IU Canada Peptides | TPT-0293

Description

Acting on the plates of the epiphysis of the tubular bones, it stimulates the growth of skeletal bones. It is identical in its composition

and effects to human pituitary growth hormone (a single-stranded polypeptide consisting of 191 amino acid

residues). Synthesized in a genetically engineered strain of E. coli.Activates the synthesis of chondroitin sulfate and collagen,

increases the excretion of hydroxyproline, promotes weight gain. Regulates protein metabolism-

stimulates the transport of amino acids into the cell and protein synthesis. Increases the number and size of muscle and liver cells

cells of the thymus, thyroid, adrenal, and gonadal glands. Mobilizes fat: lowers

cholesterol and increases triglycerides, reduces the volume of adipose tissue. Detains Na+

, K+

, phosphorus and water in the

body (prevents excretion); has an anabolic (stimulates the transport of amino acids into the cell and protein

synthesis), hyperglycemic effect (suppresses the release of insulin). Increased excretion of Ca2+ by the kidneys is

compensated by its increased absorption in the gastrointestinal tract

Special instructions

The formation of antibodies to the drug and Escherichia coli proteins is possible. . To avoid atrophy of subcutaneous fat at the injection site, it is necessary to change the injection site each time. The possible occurrence of hypothyroidism during treatment should be corrected by the introduction of TSH to achieve the effect of increasing growth (control of thyroid function). The drug is ineffective if the low growth is due to the inability of the body to synthesize growth factors or the lack of receptors for growth factors of the liver - somatomedins formed under the influence of somatropin. Patients with diabetes mellitus during treatment should be under strict medical supervision (control of glucose in the blood, urine)
Side effects

Headache, excessive fatigue or weakness, epiphyseolysis of the femoral head (limping, hip and knee pain), peripheral edema in the first weeks of treatment, arthralgia, myalgia, increased intracranial pressure (severe and frequent headaches, nausea, vomiting, visual impairment, edema of the optic disc (usually observed during the first 8 weeks of treatment, most often occurs in patients with Shereshevsky-Turner syndrome), pancreatitis (abdominal pain, nausea, vomiting), otitis media and hearing impairment (in patients with Shereshevsky-Turner syndrome)

Dosage

use of the drug with 5 units daily, injections are made subcutaneously. At the same time, it is recommended to change the injection site every time. If within two to three weeks everything will be fine, no side effects will occur, then you can safely increase the dosage twice – up to 10 units per day. You should not exceed this indicator